Iroko Pharmaceuticals files for a $145 million IPO

By
A A A

Iroko Pharmaceuticals, a drug company focused on the development and commercialization of NSAID therapeutics for patients with acute and chronic pain, filed on Tuesday with the SEC to raise up to $145 million in an initial public offering. The Philadelphia, PA-based company, which was founded in 2007 and booked $10 million in sales and royalty revenues for the 12 months ended March 31, 2013, plans to list on the NASDAQ under the symbol IRKO. Iroko Pharmaceuticals initially filed confidentially in March 2013. Jefferies and William Blair are the joint bookrunners on the deal. No pricing terms were disclosed.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks:

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

73,013,153
  • $16.18 ▼ 21.87%
40,941,366
  • $41.44 ▲ 1.69%
31,139,681
  • $118.634 ▲ 0.88%
28,207,950
  • $77.67 ▲ 2.70%
26,632,950
  • $24.02 ▲ 0.33%
24,782,057
  • $10.607 ▲ 2.09%
21,209,893
  • $39.015 ▲ 3.68%
20,916,343
  • $40.98 ▲ 3.07%
As of 11/26/2014, 03:18 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com